NCT07794670PHASE2Recruiting

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

NewAmsterdam Pharma

Start Date

9/1/2026

Completion Date

5/1/2029

Summary

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Eligibility Criteria

Age Range: 55 years to 85 years

Inclusion Criteria: * participants with preclinical AD Exclusion Criteria: * APOE genotype not meeting protocol-defined eligibility criteria

Interventions

DRUG

Obicetrapib 10 mg

DRUG

Matching placebo tablets

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Preclinical Alzheimer's Disease

Locations

K2 Medical Research

Nashville, Tennessee 37204

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Coordinate outreach and marketing across multiple sites as one effort, plus study-site logistics and tech support.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.